LANXESS successfully places EUR 500 million benchmark bond

Cologne

The specialty chemicals company LANXESS has successfully placed a 6-year-tenor euro benchmark bond with a coupon of 0.0 percent in the European capital market. LANXESS will use the funds to finance the planned acquisition of the microbial control business of US-based chemical company IFF.

The new bond is listed on the Luxembourg Stock Exchange in denominations of EUR 1,000.

“We have secured a first step of financing already quickly after the announcement of the acquisition of IFF Microbial Control and are happy about the very receptive reaction of the capital market to our offering,” said LANXESS Chief Financial Officer Michael Pontzen.

LANXESS' issuer ratings are currently Baa2 (Moody’s), BBB (Standard & Poor’s) and BBB+ (Scope). A bank consortium of active joint bookrunners comprising Citi, Société Générale and Unicredit was mandated to place the bond.

Information for editors:
All global LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com.
Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.

 

MORE ABOUT THIS TOPIC

PRESS RELEASE
Sepawa Press Release Teaser image

Focus on hygiene and health

September 20, 2024
PRESS RELEASE
Iron oxide pigments for LFP battery cathodes

LANXESS wins ICIS Innovation Award for innovative LFP battery materials

September 06, 2024
PRESS RELEASE
Since August 1, 2013, specialty chemicals Group LANXESS is steering its global business from the LANXESS Tower in Cologne.

LANXESS continues chromium oxide production in Krefeld-Uerdingen

August 21, 2024
PRESS RELEASE
LANXESS Headquarters in Cologne

LANXESS com forte fluxo de caixa e crescimento significativo dos lucros no segundo trimestre de 2024

August 20, 2024
PRESS RELEASE

Following WHO alert: LANXESS counters Mpox threat with Rely On Virkon

August 15, 2024